Merck elects Paul J. Diaz to board effective Nov. 1, 2026; board grows to 14 members

Merck & Co., Inc.

Paul J. Diaz, managing partner at Cressey & Company, joins Merck's board effective Nov. 1, 2026 and will stand for shareholder election in May 2027.
Diaz was appointed to both the Audit Committee and the Research Committee of the board.
Diaz previously served as president and CEO of Myriad Genetics and, before that, as president and CEO of Kindred Healthcare.
He also sits on the board of Centene Corporation, the Board of Trustees of Johns Hopkins Medicine and the Board of Visitors of Georgetown University Law Center.
With Diaz's addition the Merck board will consist of 14 members; he receives standard non-employee director compensation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul J. Diaz

Director

MRK · Merck & Co., Inc.

Effective: 2026-11-01
Filed: October 13, 2026, 12:36 PM ET

Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul J. Diaz was elected as Director at Merck & Co., Inc..

Action: elected
Role: Director

Exact text from the filing

Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026.

View on SEC.gov

Merck & Co., Inc. filing history →

Source: SEC EDGAR

accession 0000310158-26-000237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.